Search results - 490 results
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol
Publication Type: Peer reviewed scientific article Authors: Adriaenssens, Niels; Scholtes, Beatrice; Bruyndonckx, Robin; Jan Y Verbakel; De Sutter, An; Heytens, Stefan; Van Den Bruel, Ann; Desombere, Isabelle; Van Damme, Pierre; Goossens, Herman; Buret, L ...
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Publication Type: Peer reviewed scientific article Authors: Adriaenssens, Niels; Scholtes, Beatrice; Bruyndonckx, Robin; Van Ngoc, Pauline; Verbakel, Jan Yvan Jos; De Sutter, An; Heytens, Stefan; Van Den Bruel, Ann; Desombere, Isabelle; Van Damme, Pierre; ...
Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort studyObjectivesDesignSettingParticipantsOutcome measuresResultsConclusionsTrial registration number
Publication Type: Peer reviewed scientific article Authors: Mortgat, Laure; Verdonck, Kristien; Veronik Hutse; Isabelle Thomas; Barbezange, Cyril; Heyndrickx, Leo; Fischer, Natalie; Vuylsteke, Bea; Kabouche, Ines; Ariën, Kevin K; Desombere, Isabelle; Duys ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
that a fractional dose induces comparable antibody responses to the full dose in people <55 years. Here, we report the safety and immunogenicity of a fractional dose regimen of the BNT162 b2 vaccine. ...
Immunogenicity and one-year boostability of a 3-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-Centre clinical trial.
(days 0,3) after 12 months. Rabies neutralizing antibodies were assessed at baseline, on Day 21-28 (before 3rd PrEP dose), Day 60, Month 12 and Month 12 + 7 days. The primary outcome was one-year ...
Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
NHR, are known to have decreased antibody responses upon vaccination targeting other viral antigens. OBJECTIVES: As real-world data on vaccine responsiveness, we assessed the prevalence of SARS-CoV-2 ...
Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.
assessed by SARS-CoV-2 anti- S1 IgG antibody levels and SARSC oV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4 + and CD8 + T cell ...
Tick-Borne Encephalitis Virus Prevalence in Sheep, Wild Boar and Ticks in Belgium.
Keywords: Animals Antibodies, Viral Belgium Encephalitis Viruses, Tick-Borne Encephalitis, Tick-Borne prevalence Seroepidemiologic Studies Sheep Sus scrofa Swine Ticks Abstract: Tick-borne encephalitis virus ...
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCP s). DESIGN: Prospective cohort study with 12 months of follow-up. SETTING: Primary care in Belgium. ...
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.
assigned in a 2:1 ratio to receive either camostat mesylate or a placebo. Outcomes included change in nasopharyngeal viral load, time to clinical improvement, the presence of neutralizing antibodies ...